BioWorld

June 27, 2007

Genentech, Abbott Partner To Develop Oncology Drugs

Genentech Inc. is acting the pharma part in a deal with Abbott to advance the latter's Phase I-stage compounds ABT-263 and ABT-869, a Bcl-2 protein antagonist and VEGF receptor kinase inhibitor, respectively. (BioWorld Today) Read More

MediciNova Picks 2 Programs, Looks To Partner Most Others

Broader Comparison Finds More Specific Angiogenesis Markers

NewCo News: Cequent's RNAi Platform Draws Novartis Investment, Option

Generex Gears Up For Phase III Trial Of Oral-lyn Insulin Spray

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 6, 2025.

DNA mutations or genetic disorder concept art

Regenxbio’s Duchenne gene therapy data positive as shares falter

BioWorld

Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...

EMA warns Ozempic linked to ‘very rare’ side effect

BioWorld

The EMA’s safety committee has issued a warning that the GLP-1 receptor agonist Ozempic (semaglutide, Novo Nordisk A/S) can cause an acute eye condition in which...

Aiatella secures €2M for AI-based cardiovascular imaging tech

BioWorld MedTech

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds will be used to conduct clinical...